8 Giuseppe Giunchi

II Sessione (Francesco Cipollini, Mauro Pagani)

11:00-11:12
Regional efficacy and safety results of roxadustat compared with placebo or darbepoetin alfa in non–dialysis-dependent (NDD) chronic kidney disease (CKD) patients with anemia
Ciro Esposito
11:12-11:24
SARS-CoV2 associated venous thromboembolism – a one-year follow-up
Dimitri Peterlana
11:24-11:36
Efficacy and safety of ruxolitinib in primary/secondary myelofibrosis patients with co-morbidities and poli-pharmacy .
Endri Mauro
11:36-11:48
A new score to predict a stroke mimic in a center with a high rate of thrombolysis
Federico Moroni
11:48-12:00
The role of biomarkers in the prediction of short-time events in acute heart failure in a large population of elderly patients
Nicola Tarquinio
12:00-12:12
Rapidly progressive paucimmune glomerulonephritis following COVID-19 infection
Daniele D'ambrosio
12:12-12:24
Ten-year efficacy and safety of azathioprine treatment in the maintainance of steroid-free remission in inflammatory bowel disease patients
Claudio Cassieri
12:24-12:36
Indice di rischio e quoziente di normalizzazione: due nuovi indici per la valutazione della pressione arteriosa con ABPM. Studio su 4506 rapporti ABPM.
Giovanni Malgieri
12:36-12:48
“Long COVID” features: incidence and risk factors
Anna Maria Schimizzi
12:48-13:00
Efficacy, safety and appropriateness of the fixed-ratio combination (FRC) iGlarLixi in type 2 diabetes (T2D) in real world settings: results from the ENSURE study
Monica Larosa